1. Scrip
  2. >>Therapy Areas

First Filing, In Japan, For Daiichi’s Lead ADC As Others Progress

 
• By Ian Haydock

In a further positive step for its oncology ambitions, Japanese company files first submission for promising lead antibody-drug conjugate, partnered globally with AstraZeneca, while other pipeline ADCs mark development progress.

Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.
Daiichi's Lead ADC Filed In Japan For Breast Cancer • Source: Shutterstock

Daiichi Sankyo Co. Ltd. has submitted a new drug application in Japan for trastuzumab deruxtecan (DS-8201), its HER2-targeting lead antibody-drug conjugate (ADC), for HER2-positive metastatic breast cancer.

The Japanese filing, the first globally in any indication, marks another step towards market for the product, the subject of a huge $6.9bn ex-Japan deal with AstraZeneca PLC in March that kick-started Daiichi’s mid-term ambitions in the oncology field

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.